Major Depressive Disorder

Michael Thase, MD, explains the decision making process behind choosing drugs or therapy for patients with different types of depression.

Charles L Raison, MD, explains the relationship between mental health and the trillions of microorganisms that live in and on our bodies.

If approved, the drug could open a new line of treatment for people struggling to control symptoms despite drug therapy.

Researchers investigated the association between D2 and D3 receptor availability in the striatum and cognitive function in adults with major depressive disorder.

The use of MHW is reportedly highest in younger females with higher levels of education.

Using 24-hour wrist monitors, the study revealed “distinct mood-dependent effects on wrist-activity markers of circadian timekeeping.”

Alcohol-related disorders and mood disorders accounted for 6.8% of avoidable emergency department visits.

In a phase 2 trial, MDMA reduced PTSD in 68% of patients after a 12-months period.

The genome wide association study found that a there may be a genetic link to how depression treatments work.

A review of non-pharmacological options for treating MDD found that there was not enough evidence to support their use.

Soldiers in army units where suicide attempts occured in the past year were more likely to attempt suicide themselves.

These tools can reduce selection bias and misdiagnosis, and improve communication between primary and secondary care physicians.

Surgeons, cardiologists, pediatricians, endocrinologists and more share their thoughts on the uncertain health care climate in the US.

12% of patients prescribed the 2 drugs in combination were still taking benzodiazepine 6 months later.

Survey shows PCPs experience a lack of confidence in their own abilities to provide effective treatment for patients with mental illness.

Patients with T1D should be screened for depression and diabetes-related distress.

Patients with severe affective disorder are less likely to require psychiatric inpatient readmission within 30 days of discharge if they receive ECT.

Ketamine for treatment-resistant depression found to be efficacious and well tolerated.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

Nearly two-thirds of pediatric patients with mental health disorders are not receiving proper treatment due to inadequate screening practices.

A new meta-analysis found that 31 percent of patients in antidepressant treatment trials for persistent depressive disorder (PDD) responded to placebo and 57 percent reported adverse (nocebo) effects to them.

The survey applied a validated questionnaire to distinguish drug treatment side effects from the symptoms of major depression.

Researchers described the ten year course of primary care patients with major depression as “rather bleak.”

Associations between race/ethnicity and lack of in healthcare access were found.

Dr. Kiki Chang sits down with MD Magazine and talks about the latest data on lurasidone.

Transcranial Magnetic Stimulation (TMS) is getting good results as an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

Cognitive behavior therapy is effective when delivered online.

Mortality from serious mental illness is associated with metabolic disorder.

Study finds associations between psychiatric length of stay and readmission.

Cyberbullying exacerbates existing mental health conditions among adolescents.